Navigation Links
EquitiesIQ Initiates Coverage of Alliqua, Inc.
Date:1/14/2014

New York, NY (PRWEB) January 14, 2014

EquitiesIQ, a leading informational research provider, has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, developing, manufacturing, and marketing proprietary products to serve the wound care market.

Free report download: http://equitiesiq.com/reports/alliqua/

In late 2012, Alliqua was restructured with a seasoned management team and Board, which launched the company’s new strategy to become a leading provider of wound care products. Coincident with the new leadership, Alliqua raised capital from company insiders along with a group of retail and institutional investors. With this initial capital, Alliqua began to build its sales infrastructure and consolidate its operations.

Throughout 2013, the company entered strategic relationships with a variety of wholesale distributors including Team Distribution International, World Health Industries, McKesson Medical-Surgical, and Medline. Alliqua also secured a license agreement with sorbion GmbH & Co. to distribute wound care dressings based on sorbion’s proprietary hydroactive technology.

In November 2013, the company entered into an agreement with Celgene Corporation (CELG) to develop and market wound healing products based on Celgene Cellular Thereapeutics’ (CCT) placenta-derived technology. Products based on this technology are anticipated to have superior wound-healing characteristics, and will enable Alliqua to enter one of the fastest growing segments of the wound care market. In conjunction with the Celgene license agreement, a group of healthcare-focused institutional investors, and Celgene itself, collectively made a $14 million equity investment into the company.

Well capitalized, with its own line of value-added hydrogels, the sorbion wound
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli ... (BGI Tech), et datterselskab af BGI, verdens største ... human whole exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende ... i branchen for at levere patenterede sekvenseringsteknologier med ... typer varianter, blev købt af BGI i 2013. ...
(Date:7/22/2014)... -- Hussey Copper , a leader in copper ... announces Pullman Regional Hospital,s conversion of more than 1,100 ... surface, at a nominal cost.  This reasonably priced surface ... bacteria within 2 hours of exposure 1 and will ... diseases in its facilities. Pullman Regional Hospital, ...
(Date:7/22/2014)... WA (PRWEB) July 22, 2014 Quorum Review ... new service for large clinical trials called Quick Step™ ... is designed to address the research industry’s need for seamless ... The service is available for studies planning 50 or more ... a combined planned North American site count of 80 or ...
(Date:7/22/2014)... Lawrence, KS (PRWEB) July 22, 2014 ... as attention-deficit hyperactivity disorder (ADHD) is diagnosed, selecting medication ... trial and error. Analyzing brain patterns by using electroencephalography ... best result and thus lower the risk of adverse ... Electroencephalography Phenotypes and Biomarkers” in the current issue ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3
... (Nasdaq: CHDX ) a leading independent American provider ... of China,announced that it intends to release its financial ... Thursday, June 12, 2008., Chindex,s management will also ... 9:00 a.m. Eastern Time to discuss its financial results., ...
... Quarter ... Salesforce ... Insulet Corporation,(Nasdaq: PODD ), a leader in wearable insulin ... for,the first quarter ended March 31, 2008., First quarter 2008 ...
... Inc.,(NYSE: HSP ), a global specialty pharmaceutical ... Bowles, CFA, has been elected to,the company,s board ... expertise from leadership positions held at major,multinational consumer ... of Bowles expands Hospira,s board to nine directors, ...
Cached Biology Technology:Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7Hospira Expands Board of Directors 2
(Date:7/22/2014)... you,re allergic to dust mites (and chances are you ... at the University of Iowa have developed a vaccine ... body,s immune response. In animal tests, the nano-sized vaccine ... exposure to the allergens, according to the paper, published ... Scientists) Journal . One big reason why it ...
(Date:7/22/2014)... be on the horizon. Bacteria that produce a ... insulin resistance and other adverse effects of a ... discovered., "Of course it,s hard to speculate from ... Ph.D., assistant professor of Pharmacology. "But essentially we,ve ... in mice, even though they,re eating a high-fat ...
(Date:7/22/2014)... The challenges faced by researchers in modifying properties of ... a simple technique, thanks to recent innovative studies conducted ... , Through the use of a simple, efficient and ... NUS research teams, led by Professor Sow Chorng Haur ... of Science, demonstrated that the properties of two different ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3
... has shown that enhancing the production of a protein ... neuron death associated with Alzheimer,s, at the expense of ... amyloid-beta protein plaques within the brain is a major ... contribute to disease progression. Normally, special enzymes chew up ...
... peas to show that one copy of a gene (allele) is ... the progeny, the inherited genes are expressed at the right time ... that although gene products could be modified during the life of ... Now it appears that one copy of some genes ...
... ARLINGTON, Va., June 10 Stanley, Inc. (NYSE:,SXE), ... services,to the U.S. federal government, announced today that ... Oberon Associates, Inc. (Oberon), an,engineering, intelligence operations and ... approximately $170 million in cash,subject to certain working ...
Cached Biology News:Genome communication 2Genome communication 3Genome communication 4Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4
... an automated multiplexing platform that uses advanced ... sequence detection and pharmacogenetics applications. Multiple samples ... an open and flexible electronic microarray, the ... all tests sites have been utilized. This ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... D kit is an enzymeimmunoassay intended ... D (25-OH D) and other hydroxylated ... Our patented DIRECT assay technology eliminates ... centrifugation and therefore facilitates automation on ...
Biology Products: